弥漫大B细胞淋巴瘤CD68和CD34表达情况及临床价值

Expression and clinical value of CD68 and CD34 in diffuse large B-cell lymphoma

目的探讨弥漫大B细胞淋巴瘤(DLBCL)CD68和CD34的表达及对预后的影响。方法选取2016年5月至2019年5月该院确诊的67例DLBCL患者为研究对象。采用免疫组化法检测CD68和CD34的表达情况,分析不同特征DLBCL患者CD68、CD34的阳性表达及共表达情况,以及对预后的影响。结果67例DLBCL患者有40例CD68表达阳性,35例CD34表达阳性。Ann Arbor临床分期为Ⅲ~Ⅳ期、国际预后指数(IPI)评分为3~4分、有骨髓侵犯DLBCL患者的CD68和CD34阳性率,以及二者的共表达率明显高于Ann Arbor临床分期为Ⅰ~Ⅱ期、IPI评分为0~2分、无骨髓侵犯DLBCL患者,差异有统计学意义(P<0.05)。CD68和CD34阳性患者3年总生存率和无进展生存率均低于CD68和CD34阴性患者,差异有统计学意义(P<0.05)。结论CD68和CD34阳性表达与DLBCL患者的Ann Arbor临床分期、IPI评分、骨髓侵犯及预后情况具有一定的关系,且CD68和CD34阳性DLBCL患者预后不良。

Objective To investigate the expression of CD68 and CD34 in diffuse large B-cell lymphoma(DLBCL)and its influence on prognosis.Methods A total of 67 patients diagnosed as DLBCL in Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University from May 2016 to May 2019 were selected as the research objects.The expressions of CD68 and CD34 were detected by immunohistochemisty method,the positive expression and co-expression of CD68 and CD34 in DLBCL patients with different characteristics were analyzed,as well as the influence on prognosis.Results Among 67 DLBCL patients,40 cases were positive for CD68,and 35 cases were positive for CD34.The positive rates of CD68 and CD34,the co-expression rates of CD68 and CD34 in patients with Ann Arbor clinical stageⅢ-Ⅳ,international prognostic index(IPI)score of 3-4,bone marrow invasion were significantly higher than those in patients with Ann Arbor clinical stageⅠ-Ⅱ,IPI score of 0-2 and no DLBCL invasion,the differences were statistically significant(P<0.05).The 3-year overall survival rate and progression-free survival rate of CD68 and CD34 positive patients were lower than those of CD68 and CD34 negative patients respectively,the differences were statistically significant(P<0.05).Conclusion The positive expressions of CD68 and CD34 correlate with Ann Arbor clinical stage,IPI score,bone marrow invasion and prognosis of DLBCL patients,the prognosis of CD68 and CD34 positive DLBCL patient was poor.